Nine drugs recommended for approval by EMA/CHMP, 93 overall in 2015
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended nine new medicines for marketing authorization at its December 2015 meeting. This brings the total number of medicines recommended for approval by the CHMP in 2015 to 93.
The CHMP recommended granting a conditional marketing authorization for Tagrisso (osimertinib) for the treatment of non-small cell lung cancer (NSCLC), from AstraZeneca (LSE: AZN). The Committee reviewed Tagrisso under EMA’s accelerated assessment program. Conditional approval and accelerated assessment are two of the Agency’s main mechanisms to facilitate earlier access by patients to medicines that fulfil unmet medical needs.
Another medicine for NSCLC, Portrazza (necitumumab) from Eli Lilly (NYSE: LLY), also received a positive opinion from the Committee, for the treatment of squamous non-small cell lung cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze